US20080095825A1 - Method for Making a Reservoir Containing an Active Substance Diffused through the Reservoir and Installation Therefor - Google Patents

Method for Making a Reservoir Containing an Active Substance Diffused through the Reservoir and Installation Therefor Download PDF

Info

Publication number
US20080095825A1
US20080095825A1 US11/795,262 US79526206A US2008095825A1 US 20080095825 A1 US20080095825 A1 US 20080095825A1 US 79526206 A US79526206 A US 79526206A US 2008095825 A1 US2008095825 A1 US 2008095825A1
Authority
US
United States
Prior art keywords
tube
reservoir
product
active substance
rod
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/795,262
Other languages
English (en)
Inventor
Charles-Dominique Lafont
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Assigned to BAYER SCHERING PHARMA AKTIENGESELLSCHAFT reassignment BAYER SCHERING PHARMA AKTIENGESELLSCHAFT CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SCHERING AKTIENGESELLSCHAFT
Publication of US20080095825A1 publication Critical patent/US20080095825A1/en
Assigned to BAYER SCHERING PHARMA AKTIENGESELLSCHAFT reassignment BAYER SCHERING PHARMA AKTIENGESELLSCHAFT ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LAFONT, CHARLES-DOMINIQUE
Assigned to BAYER PHARMA AKTIENGESELLSCHAFT reassignment BAYER PHARMA AKTIENGESELLSCHAFT CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/14—Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type

Definitions

  • the invention relates to a method of producing a reservoir containing an active substance and suitable for being inserted into a natural cavity of a living being, this reservoir being enveloped by a membrane permeable to the active substance.
  • Such reservoirs are used as intrauterine contraceptive devices also called hormonal intrauterine devices.
  • This type of reservoir comprises a tubular membrane, usually made of a silicone-based material.
  • a product containing in particular a silicone-based matrix and a contraceptive hormone is enveloped by this membrane.
  • the membrane is permeable to the hormone, the latter diffusing steadily from the inside of the reservoir toward the uterine cavity.
  • Such intrauterine devices also comprise a polymer-based inert support, to which the reservoir is attached in order to hold the device in position in the uterine cavity.
  • This mode of administering contraceptive products makes it possible to use very low doses of progestative hormones, the latter being delivered directly to the target organ.
  • the effectiveness of these devices is comparable to that of hormone-based contraceptives taken by mouth.
  • Their duration of action is situated between two and five years and, unlike intrauterine devices comprising a copper wire instead of the reservoir, they are nonallergic.
  • These hormonal intrauterine devices are used in particular in cases of hypermenorrhea, which frequently occurs with copper-based intrauterine devices.
  • the membrane surrounding the reservoir is formed from a silicone tube of small diameter and the thinnest possible wall.
  • the technical constraints do not make it possible to produce silicone tubes with a wall thickness of less than 0.4 millimeter and with a diameter of less than 1.5 millimeters.
  • the diffusion of the hormone through the membrane must be slow, continuous and even, irrespective of the quantity of hormones present in the reservoir. This is possible, in application of Fick's laws on membrane diffusion, only for much thinner membranes.
  • U.S. Pat. No. 5,400,804 describes a method of making a tubular reservoir containing a contraceptive substance.
  • a tubular reservoir surrounded by a sheath, covers a needle placed in a mold. The needle injects air to increase the internal diameter of the reservoir. Once the diameter has been increased, a rod forming a support replaces the needle.
  • Such methods require the availability of a length of tube identical to the length of the cylinder of product. In other words, the latter must be made first and cut to the correct length; the same applies to the silicone tube. Furthermore, the injection of pressurized air may be inadequately controlled and/or the tube incorrectly held during this injection. It is then possible that, on the membrane of the tube, a bulge forms in which an air bubble is housed. Finally, such systems do not make it possible to effectively attach the external membrane to the internal cylinder.
  • the invention intends more particularly to remedy by proposing a method and an item of equipment for making a reservoir containing an active substance into which a thin membrane is easily placed, while preventing the formation of a bulge on this membrane.
  • the subject of the invention is a method of making a reservoir containing an active substance and suitable for being inserted into a natural cavity of a living being, this reservoir comprising a membrane that is permeable to the active substance, characterized in that it comprises steps consisting in:
  • the method may incorporate one or more of the following features:
  • the invention also relates to an installation making it possible to apply a method as described hereinabove and, more specifically, an installation that comprises:
  • These rings have an external diameter close to the external diameter desired for the reservoir.
  • FIG. 1 is a view in perspective of a hormonal intrauterine device fitted with a reservoir made according to the invention
  • FIG. 2 is a view in perspective of the reservoir of the intrauterine device of FIG. 1 ,
  • FIG. 3 is a view in perspective, on the same scale as FIG. 2 , of an empty silicone tube designed to form the membrane surrounding the reservoir of FIG. 1 ,
  • FIG. 4 is a schematic and longitudinal section, on another scale, of a first type of mold forming a means of retaining a silicone tube when the method is applied,
  • FIG. 5 is a schematic, longitudinal section, on the same scale as FIG. 4 , of a first means of injection of the product into the tube,
  • FIGS. 6 to 10 are schematic, longitudinal sections illustrating the various steps of the method using the materials of FIGS. 4 and 5 .
  • FIG. 11 is a schematic, lateral, longitudinal section of a second type of mold and of a means of injection of the product into the tube.
  • An intrauterine device 1 comprises a support 2 made of a polymer-based inert and nonallergic material.
  • This support 2 is generally T-shaped with branches 3 curved in the direction of its rod 4 , so as to be configured generally in the shape of a marine anchor.
  • a reservoir 5 is positioned on the rod 4 of the support 2 .
  • the reservoir is configured as a cylinder with a circular base and provided with a central and longitudinal opening 6 .
  • the diameter D 6 of this opening is suitable for allowing the insertion with reduced clearance of the rod 4 into the reservoir 5 .
  • the reservoir 5 is immobilized in translation on the rod 4 by two bosses 70 , 71 situated respectively in the vicinity of the ends of the rod 4 .
  • the terminal boss 70 of the rod 4 is furnished with an orifice 72 allowing threads to pass through making it easier to retract the intrauterine device from the uterine cavity.
  • the cylinder 5 comprises, in cross section, in addition to the central opening 6 , an intermediate zone between the external wall of the reservoir and the opening 6 .
  • This zone whose thickness lies generally between 1 mm and 2 mm, extends over the whole length of the reservoir 5 .
  • It is filled by a tube 8 of solid product.
  • This solid product comprises approximately 20% to 40% of an active principle, particularly a progestative hormone, for example levonorgestrel.
  • the quantity of hormone is sufficient to ensure that the device is effective for two to five years with a hormonal release of between 20 and 25 ⁇ g/24 hours which allows an effective contraceptive action.
  • the rest of the product 8 consists essentially of silicone.
  • the external wall of the reservoir 5 is formed by a continuous membrane 9 , thus producing a protective sleeve around the tube 8 . Only the terminal sections of the cylinder 5 have no membrane.
  • This membrane has a base of a silicone or a mixture of silicones. This or these silicones are advantageously of a type different from that entering into the composition of the product 8 , particularly as concerns the silica filler.
  • the tubular membrane is formed from a tube 10 which has an internal diameter D 10 approximately two to three times smaller than the external diameter D 8 of the product 8 .
  • the thickness E 10 of its wall is greater than the thickness E 5 of the final membrane 9 .
  • the thickness of the wall is inversely proportional to the external diameter of the tube.
  • the radial extension of the tube 10 allows it to surround the product 8 forming the reservoir 5 of external diameter D 5 , with a wall thickness E 5 thin enough to form a membrane.
  • the elastic properties of the silicones and their porosity make it possible to satisfy the technical constraints evoked hereinabove.
  • Other inert, nonallergic materials that are elastic, extendable, and permeable to the active substances can be used to produce a reservoir 5 via a method as described hereinafter.
  • a first type of mold in two separable parts, is made of a rigid but porous material, so as to allow humid air to pass between the interior and the exterior of the mold.
  • certain silicones polymerize in the presence of water; in this case, it is necessary to maintain a high relative humidity inside the mold.
  • the mold is made of aluminum, or of an aluminum alloy, and provided with small orifices, for example of a diameter lying between 0.2 and 0.3 mm, regularly distributed over the mold.
  • the mold may be made of a sintered material or of compressed silica.
  • the main portion 11 of the mold defines a central cylindrical housing 12 with a circular base and centered on an axis X 12 .
  • the internal diameter D 12 of the housing 12 is substantially identical to the final external diameter D 5 of the reservoir 5 .
  • a rod 13 for example a metal rod, is positioned longitudinally in the housing 12 , along the axis X 12 .
  • This rod has an external diameter D 13 corresponding substantially to the internal diameter of the finished reservoir 5 , that is to say to the diameter D 6 of the opening 6 .
  • the rod 13 is fixedly attached, at one of its ends 13 A, to a support or plate 14 , generally in the shape of a disk, with a diameter D 14 greater than the diameter D 12 .
  • the rod 13 over its whole length, passes through the mold 11 without touching the walls of the housing 12 .
  • the housing 12 communicates through a convergent 12 A with an orifice 15 having a smaller diameter than the diameter D 12 .
  • the plate 14 is placed outside the mold 11 , on the side of the outlet 12 B of the housing 12 opposite the convergent 12 A.
  • the orifice 15 allows the insertion of an end-piece of a first type of injection means represented schematically in FIG. 5 .
  • This injection means 16 generally syringe-shaped, comprises a main body 17 in which a piston 18 moves in a sealed manner.
  • This piston 18 is hollow, in order to allow the rod 13 to pass through when the insertion end-piece 19 of the body 17 is in place in the orifice 15 of the mold 11 .
  • This injection device 16 is connected, where necessary, to a reserve of product so that it can operate continuously.
  • the first step of the method of making the reservoir 5 consists in positioning, in the direction of the arrow F 1 in FIG. 6 and on the rod 13 , the silicone tube or sleeve 10 after having inserted the end-piece 19 , by force, into one end of the tube 10 .
  • the end-piece 19 of the injection system 16 is positioned in the mold as shown in FIG. 7 .
  • This product 8 which comprises the active principle, has a viscosity that varies according to the percentage of active principle.
  • the viscosity of a silicone-based product is not measured directly. It is known practice, for silicones, to indirectly assess this viscosity by measuring the speed of flow of the product under a given pressure. One method used is given by the American standard ASTM-033 in which the speed of flow is expressed in grams per minute. In this instance, the product 8 has a speed of flow greater than 2 grams per minute and preferably lying between 2.8 and 3 grams per minute.
  • the injection is made by an endless screw or a membrane system.
  • the product 8 is injected slowly, steadily and continuously for example under the action of an electric, pneumatic or mechanical force exerted on the piston 18 .
  • the quantity injected is determined in order to substantially fill the annular volume 20 available in the silicone tube 10 thus retained in the housing 12 .
  • This injection takes place without notable radial and/or longitudinal deformation of the tube 10 , because of the quantity injected and the speed of injection. Furthermore, the mold holds the tube 10 in place.
  • the end 21 of the tube 10 As shown in FIGS. 7 and 8 , the end 21 of the tube 10 , opposite the orifice 15 remains open throughout the period of injection of the product 8 .
  • the filling being made easier by the opening of the end 21 , which allows all the residual air to be expelled from the volume 20 , the piston 18 is still not abutting against the end-piece 19 inserted in the end of the mold fitted with the orifice 15 , because of the quantity of product 8 initially present in the device 16 as shown in FIG. 8 .
  • the tube 10 is entirely filled by the product 8 , except for the volume occupied by the rod 13 .
  • the product is uniformly distributed in the annular space 20 . It is particularly free of air bubbles in the vicinity of the wall of the tube 10 .
  • the end 21 of the tube 10 is blanked off by the plate 14 because of its movement in the direction of the arrow F 3 by sliding along the rod 13 .
  • the plate 14 then closes the outlet 12 B and the end 21 of the tube 10 .
  • Only a passage for the rod 13 is preserved in the closure system.
  • the rod 13 is immobilized, for example, by a jaw device, a guillotine valve device.
  • the end 21 and the outlet 12 B are closed by a guillotine or pincer system. This blanking off of the end 21 being carried out, the product 8 can no longer be expelled through this end of the tube 10 opposite to the syringe 16 .
  • the injection of the product 8 into the tube 10 in the direction of the arrow F 4 continues. This second injection takes place under a greater pressure than the first. Because of the elastic properties of the wall 9 of the silicone tube 10 , the latter dilates radially in the direction of the arrows F 5 and F′ 5 until coming into contact with the internal face 11 A of the mold 11 which defines the housing 12 . Because the pressure exerted by the product 8 on the wall 9 is constant and uniformly distributed on this wall 9 , the tube 10 is dilated while preventing any bulge and while producing a wall 9 whose final thickness is even at all points of the wall. This forms a membrane whose porosity and diffusion coefficient are optimal and even.
  • the quantity of product 8 injected during this step is particularly a function of the final diameter D 5 of the reservoir 5 , that is to say, in practice, a function of the internal diameter D 12 of the housing 12 .
  • the injection is terminated when the external face of the wall 9 of the tube 10 and the internal face 11 A of the mold 11 are in contact over the whole of their respective surface.
  • the internal face 11 A is not smooth but has asperities, not shown, sufficiently large to form coupling points of the wall 9 of the tube 10 thus preventing its retraction and/or its longitudinal extension during the injection of the product 8 and/or the polymerization.
  • the rod 13 is withdrawn from the mold 11 in the direction of the arrow F 6 in FIG. 10 , which allows the reservoir 5 to be extracted from the housing 12 .
  • the rod may then be extracted from the reservoir.
  • an adhesion of the product 8 on the rod 13 may compromise an easy retraction of the latter from the mold 11 .
  • the rod 13 is covered with a material that does not adhere to the rod 13 .
  • a sheath 130 is made of a material that is biocompatible and inert relative to the other components of the intrauterine device 1 .
  • This sheath 130 is positioned on the rod 13 prior to the latter being installed in the mold 11 .
  • this sheath 130 helps the seal between the ends of the rod 13 with the piston 18 and the plate 14 .
  • the sheath 130 is replaced by a surface coating of the rod 13 that does not adhere to the product 8 .
  • the material forming the rod 13 itself does not adhere to the product 8 .
  • the mold 11 may be formed of two matching half-shells together defining the housing 12 . In this case, after the polymerization, the mold is opened to allow the retraction of the reservoir 5 .
  • the aforementioned assembly is cut to the desired length as a function of the length of the rod 4 that is then inserted into the opening 6 .
  • the length of the housing 12 may make it possible to produce several reservoirs 5 end-to-end.
  • the mold 11 comprises several grooves 12 placed in parallel and/or in a star shape, thus allowing the simultaneous and parallel production of several reservoirs.
  • the injection device 16 is adapted accordingly.
  • the injection device 16 is fitted with a means of continuously supplying the main body 17 with the product 8 .
  • the mold 11 has no rod similar to the rod 13 .
  • the reservoir obtained is a full cylinder. It is then necessary to produce a support different from that previously described. This may be, for example, a support fitted with open ring type coupling means.
  • the installation comprises a mold 11 whereof the length of the housing 12 is shorter than that described.
  • These molds are suitable for receiving, instead of the central rod 13 , the rod 4 of a support 2 .
  • the hormonal intrauterine device is produced, in a single operation ready for use, by overmolding the reservoir 5 onto the rod 4 .
  • the length of the housing 12 corresponds substantially to the length of the intrauterine device 1 , the cutting step being no longer necessary.
  • FIG. 11 illustrates another type of mold and another means of injecting the product according to the invention.
  • This other mold 22 comprises a bottom half-mold 23 and a top half-mold 24 .
  • the mold 22 is made of a material similar to that of the mold 11 in order to allow the retention of a high relative humidity in the mold.
  • the bottom half-mold 23 comprises a central housing 25 A of dimensions and shape adapted to the desired dimensions of the reservoir 5 .
  • the housing 25 A is semicylindtical with a circular base. In the vicinity of the ends of this housing 25 A, cut-outs 26 are made.
  • the end sections of the half-mold 23 are fitted, in the top portion, with a groove 27 .
  • These grooves 27 have a shape and dimensions suitable for receiving the rod 13 .
  • the top half-mold 24 is similar to the half-mold 23 . It comprises a semicylindrical central housing 25 B with a circular base. This housing 25 B, similar to the housing 25 A, has dimensions and a shape adapted to the desired dimensions of the reservoir 5 .
  • the half-mold 24 is fitted with grooves 27 and cut-outs 26 of shapes and dimensions similar to those of the half-mold 23 .
  • the cut-outs 26 and the grooves 27 of each half-mold 23 , 24 are advantageously placed facing one another when the mold 22 is closed.
  • the mold 22 comprises a central housing 25 formed by the housings 25 A and 258 of the half-molds 23 and 24 .
  • the half-mold 24 is provided with two orifices 28 , 29 placed in the vicinity of its ends. These orifices 28 , 29 are perpendicular to a longitudinal axis X 25 of the housing 25 B when the mold is closed. They allow a communication between the outside of the mold 22 and the housing 25 when the mold is closed.
  • the orifice 28 is a through-orifice and opens into the housing 25 B, between a cut-out 26 and the end wall 25 C of the housing 25 B.
  • the external outlet of this orifice has an internal diameter close to the external diameter of the end-piece 19 of a syringe 16 .
  • the orifice 29 made on the other end of the half-mold 24 forms a blind compartment.
  • This orifice is traversed, in the vicinity of its closed end, by a channel 30 .
  • This channel is oriented in a direction generally parallel to the axis X 25 when the mold is closed.
  • the channel 30 connects the outside and the housing 25 .
  • This channel 30 receives a stopping member 31 , for example a pin made of rigid polymer. This pin 31 can be moved in the channel 30 in order to stop the latter and prevent, any communication, via the channel 30 or the orifice 29 , between the housing 25 and the outside.
  • the orifice 28 is also traversed by a channel 32 in which a stopping member 33 in the form of a pin moves.
  • This channel 32 is blind, its closed end being situated in the wall of the half-mold 24 . It is placed in the vicinity of the outlet of the orifice 28 .
  • the channel 32 is oriented parallel to the axis X 25 when the mold is closed.
  • These stopping members 31 , 33 have a length and a diameter that are sufficient to stop the corresponding channels 30 , 32 in a sealed manner.
  • a positioning member 34 When it is desired to produce an intrauterine device 1 , the user inserts, at each end of a tube 10 , for example by means of a spreader-type plier, a positioning member 34 .
  • This member is formed by a ring 34 made of a rigid, inert and biocompatible material.
  • This ring 34 is fitted with a radial collar 35 extending outward.
  • the internal diameter D 34 of the ring 34 is close to the desired external diameter D 5 of the reservoir 5 .
  • the rod 13 also covered by a sheath 130 similar to that mentioned hereinabove, is then inserted into the opening of the tube 10 .
  • the assembly is then positioned in the bottom half-mold 23 , so that the ends of the rod 13 rest in the grooves 27 .
  • the tube 10 is positioned in the half-mold 23 so that the collars 35 of the end rings 34 are inserted, with reduced clearance, into the corresponding cut-outs 26 .
  • the mold 22 is closed by folding down the top half-mold 24 .
  • the grooves 27 and the cut-outs 26 of the half-mold 24 cover the free portions of the rod 13 and of the collars 35 .
  • the tube 10 and the rod 13 are retained and positioned exactly in the mold 22 .
  • the product 8 in paste form is injected through the orifice 28 after the end-piece 19 of a syringe has been inserted into the outlet of the latter.
  • the pin 33 is in the retracted position in order to allow the product to pass into the housings 25 A and 25 B.
  • the product 8 enters the tube 10 .
  • the air contained in the tube 10 is expelled from the mold 22 and exits via the orifice 29 whose passage is free, the pin 31 being in the retracted position.
  • the orifice 29 is stopped by pushing the pin 31 in the direction of the housing 25 B.
  • the injection of the product 8 is then continued until the desired diameter of the reservoir 5 is obtained.
  • the tube 10 is held in place by the rings 34 . There may therefore be no longitudinal expansion of the tube 10 ; only radial expansion is permitted.
  • the injection orifice 28 is stopped by pushing the pin 33 to the end of the channel 32 .
  • the polymerization takes place in a humid environment in a manner similar to that previously described.
  • the mold is opened and the rod 13 which slides freely inside the sheath 130 is easily withdrawn.
  • the reservoir is cut to the desired length. This cut is made particularly at the rings 34 .
  • the user places several molds, 22 in parallel, supplied by a syringe-type device with multiple end-pieces in order to produce several reservoirs 5 in parallel.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Injection Moulding Of Plastics Or The Like (AREA)
  • Casting Or Compression Moulding Of Plastics Or The Like (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Prostheses (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
US11/795,262 2005-01-25 2006-01-24 Method for Making a Reservoir Containing an Active Substance Diffused through the Reservoir and Installation Therefor Abandoned US20080095825A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0500758 2005-01-25
FR0500758A FR2881046A1 (fr) 2005-01-25 2005-01-25 Procede de fabrication d'un reservoir contenant une substance active diffusant a travers le reservoir et installation pour sa mise en oeuvre
PCT/FR2006/000159 WO2006079709A2 (fr) 2005-01-25 2006-01-24 Procede de fabrication d'un reservoir contenant une substance active diffusant a travers le reservoir et installation pour sa mise en oeuvre

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/000159 A-371-Of-International WO2006079709A2 (fr) 2005-01-25 2006-01-24 Procede de fabrication d'un reservoir contenant une substance active diffusant a travers le reservoir et installation pour sa mise en oeuvre

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/784,384 Continuation US9351868B2 (en) 2005-01-25 2013-03-04 Method for making a reservoir containing an active substance diffused through the reservoir and installation therefor

Publications (1)

Publication Number Publication Date
US20080095825A1 true US20080095825A1 (en) 2008-04-24

Family

ID=34953682

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/795,262 Abandoned US20080095825A1 (en) 2005-01-25 2006-01-24 Method for Making a Reservoir Containing an Active Substance Diffused through the Reservoir and Installation Therefor
US13/784,384 Expired - Fee Related US9351868B2 (en) 2005-01-25 2013-03-04 Method for making a reservoir containing an active substance diffused through the reservoir and installation therefor

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/784,384 Expired - Fee Related US9351868B2 (en) 2005-01-25 2013-03-04 Method for making a reservoir containing an active substance diffused through the reservoir and installation therefor

Country Status (19)

Country Link
US (2) US20080095825A1 (ko)
EP (1) EP1841389B1 (ko)
JP (1) JP4870688B2 (ko)
KR (1) KR101244359B1 (ko)
CN (1) CN100438837C (ko)
AT (1) ATE548014T1 (ko)
AU (1) AU2006208822A1 (ko)
BR (1) BRPI0607221A2 (ko)
CA (1) CA2589015C (ko)
EA (1) EA010767B1 (ko)
ES (1) ES2383456T3 (ko)
FR (1) FR2881046A1 (ko)
HK (1) HK1112386A1 (ko)
IL (1) IL183517A0 (ko)
MX (1) MX2007008765A (ko)
NO (1) NO20074337L (ko)
NZ (1) NZ560802A (ko)
WO (1) WO2006079709A2 (ko)
ZA (1) ZA200707178B (ko)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102188303A (zh) * 2010-03-17 2011-09-21 上海伦屹光电科技有限公司 辅助放取和检查节育环的可视设备及其实现方法
EP2482768A1 (en) * 2009-10-01 2012-08-08 Bayer Oy An intrauterine system
WO2013009674A2 (en) 2011-07-11 2013-01-17 Medicines360 Intraurinary systems, iud insertion devices, and related methods and kits therefor
US20150202076A1 (en) * 2012-08-09 2015-07-23 Mithra Pharmaceuticals S.A. Intrauterine Device
US9351868B2 (en) 2005-01-25 2016-05-31 Bayer Oy Method for making a reservoir containing an active substance diffused through the reservoir and installation therefor
USD829390S1 (en) * 2016-12-23 2018-09-25 Jurox Pty Ltd Intravaginal device
WO2020172246A2 (en) 2019-02-19 2020-08-27 Medicines360 Devices, systems, methods and kits for insertion and removal of iuds
US20220273487A1 (en) * 2008-09-17 2022-09-01 Bayer Oy Inserter
US11571328B2 (en) 2018-04-09 2023-02-07 Medicines360 IUD insertion devices
US11872155B2 (en) 2008-09-17 2024-01-16 Bayer Oy Inserter
US11992431B2 (en) 2008-09-17 2024-05-28 Bayer Oy Inserter

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2057972A1 (en) * 2007-11-07 2009-05-13 N.V. Organon Intrauterine deposit
FR2927798B1 (fr) * 2008-02-25 2011-03-04 C L Investissements Procede de fabrication d'un dispositif contraceptif intra-uterin et installation pour la mise en oeuvre de ce procede
FR2927799B1 (fr) * 2008-02-25 2011-03-04 C L Investissements Procede de mise en place d'une membrane autour d'un element contenant une substance active et installation de mise en oeuvre de ce procede
FI20085277A0 (fi) * 2008-04-02 2008-04-02 Bayer Schering Pharma Oy Kohdunsisäinen järjestelmä
US8568374B2 (en) 2009-05-04 2013-10-29 Merck Sharp & Dohme B.V. Intrauterine system

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920727A (en) * 1987-12-30 1990-05-01 Huhtamaki Oy Cassette system and apparatus for manufacturing an active agent liberating capsule for subcutaneous use
US5230207A (en) * 1991-03-28 1993-07-27 Rolf Hartzell Equipment for manufacturing of subcutaneous capsules
US5369943A (en) * 1992-07-31 1994-12-06 Leiras Oy Equipment for providing a medicine rod with a shell
US5400804A (en) * 1992-07-31 1995-03-28 Leiras Oy Method and an equipment for installing a medicine capsule on a support
US20060016451A1 (en) * 2002-09-18 2006-01-26 Esa Hallinen Delivery sysem and a manufacturing process of a delivery system

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5317849A (en) * 1992-08-07 1994-06-07 Sauter Manufacturing Corporation Encapsulation equipment and method
CN1137668C (zh) * 2000-11-01 2004-02-11 周星 避孕气囊栓塞装置
FR2881046A1 (fr) 2005-01-25 2006-07-28 7 Med Ind Sa Procede de fabrication d'un reservoir contenant une substance active diffusant a travers le reservoir et installation pour sa mise en oeuvre

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920727A (en) * 1987-12-30 1990-05-01 Huhtamaki Oy Cassette system and apparatus for manufacturing an active agent liberating capsule for subcutaneous use
US5230207A (en) * 1991-03-28 1993-07-27 Rolf Hartzell Equipment for manufacturing of subcutaneous capsules
US5369943A (en) * 1992-07-31 1994-12-06 Leiras Oy Equipment for providing a medicine rod with a shell
US5400804A (en) * 1992-07-31 1995-03-28 Leiras Oy Method and an equipment for installing a medicine capsule on a support
US20060016451A1 (en) * 2002-09-18 2006-01-26 Esa Hallinen Delivery sysem and a manufacturing process of a delivery system

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9351868B2 (en) 2005-01-25 2016-05-31 Bayer Oy Method for making a reservoir containing an active substance diffused through the reservoir and installation therefor
US11911312B2 (en) 2008-09-17 2024-02-27 Bayer Oy Inserter
US11872155B2 (en) 2008-09-17 2024-01-16 Bayer Oy Inserter
US11850182B2 (en) 2008-09-17 2023-12-26 Bayer Oy Inserter
US11992431B2 (en) 2008-09-17 2024-05-28 Bayer Oy Inserter
US20220273487A1 (en) * 2008-09-17 2022-09-01 Bayer Oy Inserter
US9949869B2 (en) 2009-10-01 2018-04-24 Bayer Oy Intrauterine system
EP2482768A4 (en) * 2009-10-01 2014-03-12 Bayer Oy INTRAUTERINES SYSTEM
EP2482768A1 (en) * 2009-10-01 2012-08-08 Bayer Oy An intrauterine system
CN102188303A (zh) * 2010-03-17 2011-09-21 上海伦屹光电科技有限公司 辅助放取和检查节育环的可视设备及其实现方法
US10028858B2 (en) 2011-07-11 2018-07-24 Medicines360 Intrauterine systems, IUD insertion devices, and related methods and kits therefor
US12004992B2 (en) 2011-07-11 2024-06-11 Medicines360 Kits for intrauterine systems and IUD insertion devices
US11090186B2 (en) 2011-07-11 2021-08-17 Medicines360 Methods for using intrauterine systems and IUD insertion devices
WO2013009674A2 (en) 2011-07-11 2013-01-17 Medicines360 Intraurinary systems, iud insertion devices, and related methods and kits therefor
US20150202076A1 (en) * 2012-08-09 2015-07-23 Mithra Pharmaceuticals S.A. Intrauterine Device
USD829390S1 (en) * 2016-12-23 2018-09-25 Jurox Pty Ltd Intravaginal device
US11571328B2 (en) 2018-04-09 2023-02-07 Medicines360 IUD insertion devices
EP4378464A2 (en) 2018-04-09 2024-06-05 Medicines360 Iud insertion device
WO2020172246A2 (en) 2019-02-19 2020-08-27 Medicines360 Devices, systems, methods and kits for insertion and removal of iuds

Also Published As

Publication number Publication date
EP1841389B1 (fr) 2012-03-07
CA2589015A1 (fr) 2006-08-03
AU2006208822A1 (en) 2006-08-03
HK1112386A1 (en) 2008-09-05
IL183517A0 (en) 2007-09-20
US9351868B2 (en) 2016-05-31
WO2006079709A3 (fr) 2006-09-21
AU2006208822A2 (en) 2006-08-03
ES2383456T3 (es) 2012-06-21
BRPI0607221A2 (pt) 2009-08-18
EP1841389A2 (fr) 2007-10-10
KR101244359B1 (ko) 2013-03-18
CN101090683A (zh) 2007-12-19
EA010767B1 (ru) 2008-10-30
US20140076327A1 (en) 2014-03-20
ATE548014T1 (de) 2012-03-15
NO20074337L (no) 2007-08-24
NZ560802A (en) 2009-07-31
MX2007008765A (es) 2008-02-25
CA2589015C (fr) 2011-05-24
KR20070101287A (ko) 2007-10-16
JP2008528154A (ja) 2008-07-31
FR2881046A1 (fr) 2006-07-28
WO2006079709A2 (fr) 2006-08-03
JP4870688B2 (ja) 2012-02-08
ZA200707178B (en) 2009-03-25
CN100438837C (zh) 2008-12-03
EA200701379A1 (ru) 2007-12-28

Similar Documents

Publication Publication Date Title
US9351868B2 (en) Method for making a reservoir containing an active substance diffused through the reservoir and installation therefor
US4341728A (en) Method for making an IUD with shrinking of a medicated attachment onto a support
US5632777A (en) Method of inflating a prosthesis
US7963909B2 (en) Methods of manufacturing fluid reservoirs for penile implant devices
CN102164561A (zh) 牙科排龈线供给装置
US3748209A (en) Apparatus for making implant capsules
EP0082894B1 (en) Method of making intrauterine devices
FI76687B (fi) Foerfarande foer framstaellning av en kombination av en intrauterin anordning och en laekemedel frigoerande del.
US6561804B2 (en) One-way receptacle for dental filling material
CA1176931A (en) Intrauterine devices and method and apparatus for making the same
SU1736468A1 (ru) Устройство дл изготовлени зубных протезов
AU706502B2 (en) Testicular prosthesis and method of manufacturing and filling
JPH04164632A (ja) 中空モールの製造方法
JPH06218062A (ja) 子宮内装着用薬物放出器具

Legal Events

Date Code Title Description
AS Assignment

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:SCHERING AKTIENGESELLSCHAFT;REEL/FRAME:020110/0334

Effective date: 20061229

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT,GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:SCHERING AKTIENGESELLSCHAFT;REEL/FRAME:020110/0334

Effective date: 20061229

AS Assignment

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LAFONT, CHARLES-DOMINIQUE;REEL/FRAME:023587/0190

Effective date: 20070722

AS Assignment

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:BAYER SCHERING PHARMA AKTIENGESELLSCHAFT;REEL/FRAME:027747/0619

Effective date: 20110706

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION